# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2016

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2016-05-13
- Accepted by EDGAR: May 13, 2016, 12:41 ET
- Period: 2016-03-31
- Accession: 0001078782-16-002789
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000107878216002789/f10q033116_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000107878216002789/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $0 | us-gaap:Revenues |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | −$2.5k | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2016-01-01 to 2016-03-31 | −$5.1k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2016-01-01 to 2016-03-31 | $0 | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2016-03-31 | $216 | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $216 | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $216 | us-gaap:Assets |
| Total liabilities | at 2016-03-31 | $171.0k | us-gaap:Liabilities |
| Shareholders' equity | at 2016-03-31 | −$188.9k | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 5,840 characters.

### Forward-Looking Statement Notice

This Form 10-Q contains certain forward-looking statements. For this purpose any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; changes in rules or regulations relating to shell companies; technological advances and failure to successfully develop business relationships.

### Overview

### General

Jolley Marketing, Inc. was incorporated on December 3, 1998, in the State of Nevada. Our Company has assets of nominal value and we have generated no revenue since September 2008. We are a “shell company” as defined pursuant to Rule 12b-2 under the Securities Exchange Act of 1934 (the “Exchange Act”). We intend to seek to acquire the assets or voting securities of one or more other companies that are actively engaged in a business that generates revenues in exchange for securities of our Company, or to be acquired by such a company.

As disclosed in Note 7 above, we have entered into an Agreement and Plan of Merger to acquire Creative Medical Technologies, Inc., a Nevada corporation (“CMT”), which we anticipate will close on May 18, 2016.

Our Company currently intends to remain a shell company until a merger or acquisition is consummated. We currently anticipate that our Company’s cash requirements will be minimal until we complete such a merger or acquisition and that our sole director and officer, or his affiliates, will provide the financing that may be required for our limited operations prior to completing such a transaction. We currently have no employees. Our sole director and officer has agreed to allocate a portion of his time to the activities of our Company, without cash compensation. He anticipates that we can implement our business plan by devoting a portion of his available time to our business affairs.

### Three Month Periods Ended March 31, 2015 and 2016

#### Revenue

Our revenues for the three months ended March 31, 2015 and 2016, were $0 and $0, respectively.

#### Operating Expenses

For the three months ended March 31, 2015, operating expenses were $9,272, consisting of $6,892 in professional fees and other income (expense) was $2,380 consisting of interest expense of $2,280 and other general expenses of $100. For the three months ended March 31, 2016, operating expenses were $2,522, consisting of $2,522 in professional fees and other general and administrative costs of $0. Other income (expense) was $2,618, consisting of interest expense of $2,618. The Company's interest expense increased during the three months ended March 31, 2015 as compared to the three months ended March 31, 2016, due to an increase in the notes payable.

#### Net Loss

Our net losses for the three months ended March 31, 2015 and 2016 were $9,272 and $5,140, respectively, which resulted in a net loss per share of $0.00 for each period.

#### Liquidity and Capital Resources

The Company’s balance sheet as of March 31, 2016, reflects total current assets of $216, consisting of cash. As of March 31, 2016, our current liabilities were $170,960 which included $19,601 in accounts payable, $111,700 in notes payable to related parties, and $39,659 in interest payable. Long-term debt of $18,200 on the balance sheet consists of notes payable to related parties.

We anticipate our expenses to be limited to accounting, auditing, legal and filing fees associated with continuing our reporting status with the Securities and Exchange Commission (the "SEC") along with miscellaneous expenses related to our corporate existence. We estimate our ongoing expenses to be $30,000 per year. We do not have any commitments for capital expenditures nor do we anticipate entering into any such commitments. We will likely need additional funds to cover our expenses for the next year.

In the past we have relied on advances from related parties to cover our operating costs. Management anticipates that we will receive sufficient advances to meet our needs through the next 12 months. However, there can be no assurances to that effect. Our need for capital may change dramatically if we acquire an interest in a business opportunity during that period. Further, we cannot assure that we will be successful in consummating any acquisition on favorable terms or that we will be able to profitably manage any business venture we acquire. Should we require additional capital, we may seek additional advances from officers, sell common stock or find other forms of debt financing.

We have no other assets or line of credit, other than that which present management may agree to extend to or invest in us, nor do we expect to have one before a merger is affected. We will carry out our business plan, as discussed above. We cannot predict to what extent our liquidity and capital resources will be diminished prior to the consummation of a business combination or whether our capital will be further depleted by operating losses (if any) of the business entity which we may eventually acquire.

Our current operating plan is to continue searching for potential businesses, products, technologies and companies for acquisition and to handle the administrative and reporting requirements of a public company.

## Controls and procedures

As filed, 1,209 characters.

**Evaluation of Disclosure Controls and Procedures.** Our management, with the participation of our president, who is also our principal financial officer, carried out an evaluation of the effectiveness of our "disclosure controls and procedures" (as defined in the Exchange Act Rule 13a-15(e)) as of the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our president concluded that, as of the Evaluation Date, our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (ii) is accumulated and communicated to our management, including our president, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control Over Financial Reporting.** There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Filed May 13, 2016.
Source: SEC EDGAR, the filing index for accession 0001078782-16-002789. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
